Technologies for OUD Prevention, Control and Supportive Care - Development of Patient/Caregiver mobile application and Provider Dashboard

OUD 预防、控制和支持护理技术 - 开发患者/护理人员移动应用程序和提供商仪表板

• 批准号: 10259108
• 负责人: SATHYA ELUMALAI
• 金额: $ 22.12万
• 依托单位: AIDAR HEALTH, INC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10259108
• 关键词: Accounting; Adherence; Adult; Adverse event; American; Analgesics; Arts; Award; Awareness; Behavioral; Biological Markers; Biological Products; Breathing; Businesses; Cardiopulmonary; Cardiovascular system; Caregiver support; Caregivers; Caring; Cessation of life; Characteristics; Chronic; Chronic Disease; Client satisfaction; Clinical; Clinical Research; Collection; Communities; Computer software; Cues; Data; Data Science; Data Set; Deterioration; Development; Devices; Disease; Drug Kinetics; Drug usage; Early Diagnosis; Effectiveness; Emergency Department Physician; Emergency Situation; Enrollment; Exercise; Expectancy; Fentanyl; Fostering; Freedom; Frequencies; Friends; Generations; Goals; Health; Health Professional; Health behavior; Healthcare; Heart Rate; Heroin; Home; Hospitals; Human; Improve Access; Individual; Intervention; Interview; Knowledge; Legal patent; Libraries; Life Style; Light; Link; Longitudinal trends; Low income; Lung; Machine Learning; Measurement; Measures; Mediating; Medical; Mission; Modeling; Monitor; Moods; Morphology; Non-Malignant; Nurses; Occupations; Opioid; Opioid Analgesics; Outcome; Overdose; Pain; Pain management; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Physicians; Physiology; Postoperative Pain; Prevention; Probability; Problem Solving; Process; Property; Provider; Quality of Care; Quality of life; Questionnaires; Reporting; Secure; Self Efficacy; Shock; Signal Transduction; Societies; Spirometry; Street Drugs; Support System; Supportive care; Surveys; Symptoms; System; Technology; Testing; Time; TimeLine; Titrations; Training; Unemployment; Uninsured; Ventilatory Depression; Visit; Voice; addiction; base; behavioral health; biophysical properties; chronic pain; clinical care; cohort; craving; dashboard; data access; digital; electronic consent; evidence base; experience; functional outcomes; health assessment; heart rate variability; improved; improved outcome; informal caregiver; innovation; insight; loved ones; mental state; misuse of prescription only drugs; mobile application; mortality; nutrition; opioid epidemic; opioid misuse; opioid overdose; opioid use; outreach program; overdose death; pain relief; phrases; point of care; precision medicine; prescription opioid; pressure; product development; remote monitoring; respiratory; response; side effect; social determinants; software development; software infrastructure; synthetic drug; therapy development; tool; trend; virtual

ABSTRACT Pain is an important issue for both society and health care. The increasing frequency of individuals with chronic pain as the result of chronic diseases and postoperative pain have directly led, over the past two decades, to the over-prescription and misuse of opioids. In early 2019, an estimated 130 people per day were dying from opioid- related drug overdoses, 2 million people were misusing first-time opioid prescriptions, and almost 33000 deaths were attributed to overdosing with synthetic non-methadone opioids in the USA alone. Even though respiratory depression and complete respiratory arrest are the major causes of mortality with opioid overdose, there is currently a serious knowledge gap in our understanding of the underlying mechanisms of opioid pain relief and respiratory depression by opioids, and how these mechanisms differ from each other. Aidar Health’s ground- breaking technology offers a rapid medical assessment device, MouthLab, which non-invasively measures 10+ vital medical parameters in under 60 seconds, and an enterprise platform that leverages data science, to create a new kind of precision medicine through clinical-grade monitoring, at home. A point-of-care solution such as MouthLab is fundamental in understanding the impact of prescribed opioids and synthetic drugs, its impact on the underlying chronic condition and effectiveness of mitigation strategies. Powered by AI and machine learning, Aidar’s proprietary software would be able to provide deeper, real-time insights of subtle changes in physiology to assist the provider with decisions related to drug titration, treatment changes, adjunct therapies before any adverse event can occur. MouthLab’s ability to combine a wide-ranging spectrum of cardiopulmonary measurements (i.e. SpO2, Heart rate, Heart rate variability, Respiratory Rate, Respiratory Flow Cycle Morphology, Spirometry), would be able to solve the problem of lack of real-time health insights which would have significant relevance to providers in the treatment development process through the collection of multiple biomarker data linked to opioid-induced respiratory depression. This product creates a fundamental shift in the technology employed at home by identifying early warning symptoms through a multiparameter approach and facilitates understanding of the underlying mechanisms linking pain relief with control of breathing to identify pain therapies with minimal or no respiratory side effects. The novelty is affirmed with two approved patents and the freedom to operate analysis that found no prior art of concern. The goal of this project is to develop software infrastructure that would enhance the progressive and holistic monitoring of users experiencing OUD. By the end of this award, the company will test and validate the newly developed software capabilities in a small cohort of patients and controls at TentHouse Health & Wellness. Our solution has a validated business model (through over 100 consumers at Johns Hopkins Hospital and with 6 Pharmaceutical customer interviews) that drive value for patients, physicians, biopharmaceuticals, and payers. A successful development of this product is forecast to create 43 new jobs (2022) with an annual payroll exceeding $11.5M. As a direct result of this award, this innovative product can reach the U.S. market in 2022, with $123M in projected revenue by 2025. Our mission is to empower the uses and improve the quality of life of every individual with OUD. MouthLab will essentially be like a ‘Check Engine’ light for individual with OUD.

抽象的 痛苦是社会和医疗保健的重要问题。慢性个体的频率不断增加 在过去的二十年中，由于慢性疾病和术后疼痛的疼痛直接导致 过度处方和杀oopioids。 2019年初，估计每天有130人死于opioid- 相关药物过量，200万人缺少阿片类药物处方，近33000人死亡 仅在美国，仅合成非甲二酮阿片类药物就归因于药物过量。即使呼吸 抑郁症和完全呼吸道停滞是阿片类药物过量死亡的主要原因，有 目前，我们了解阿片类药物缓解和 卵毒素的呼吸抑制以及这些机制如何彼此不同。艾达尔·健康（Aidar Health）的地面 Breaking Technology提供了快速的医疗评估设备，Luslab，该设备非侵入性地尺寸为10+ 在60秒内，重要的医疗参数以及利用数据科学的企业平台来创建 通过临床级监测，一种新型的精确药物。护理点解决方案，例如 Hususlab是理解规定的阿片类药物和合成药物的影响的基础，其对 缓解策略的基本慢性状况和有效性。由AI和机器学习提供动力， 艾达尔（Aidar）的专有软件将能够提供对生理学细微变化的更深入的实时见解 为了帮助提供者做出与药物滴定有关的决定，治疗更改，辅助疗法 可能发生不良事件。 Muthlab的能力结合了大型心肺的范围 测量值（即SPO2，心率，心率变异性，呼吸率，呼吸道周期 形态学，肺活量测定法）将能够解决缺乏实时健康见解的问题 通过收集多个 生物标志物数据与阿片类药物诱导的呼吸抑郁症有关。该产品在 技术在家中通过多参数方法识别预警符号和 促进对将疼痛缓解与控制呼吸联系起来的基本机制的理解以识别疼痛 具有最小或无呼吸副作用的疗法。新颖性受到两项批准的专利的影响， 没有发现先前关注的艺术的操作分析自由。该项目的目的是开发软件 基础架构将增强对体验OUD用户的渐进和整体监控。到最后 在该奖项中，该公司将在一小部分中测试和验证新开发的软件功能 Tenthouse Health＆Wellness的患者和对照。我们的解决方案具有经过验证的业务模型（通过 约翰·霍普金斯医院的100多名消费者和6次药物访谈）驱动价值 适用于患者，医生，生物制药和付款人。预计该产品的成功开发是 创建43个新工作（2022），年薪超过1,150万美元。作为该奖项的直接结果， 创新产品可以在2022年到达美国市场，到2025年，预计收入为1.23亿美元。我们的使命是 赋予用途并改善每个人的生活质量。嘴巴本质上将是 就像带有Oud个人的“检查引擎”灯。